Medicine and Dentistry
Acute Myeloid Leukemia
15%
Agents Acting on the Eye
15%
Anaplastic Large Cell Lymphoma
5%
Anaplastic Lymphoma Kinase
9%
Anthracycline
15%
Attributable Risk
5%
B Cell
17%
Cancer Cell
5%
Cancer Cell Line
15%
Cell Death
5%
Charlson Comorbidity Index
10%
Chemotherapy
5%
CHOP
10%
Clinical Stage
7%
Clinical Trial
20%
Cohort Analysis
49%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Diffuse Large B-Cell Lymphoma
100%
Disability Pension
15%
Diseases
8%
Drug Effect
15%
Event Free Survival
7%
Exome
5%
Gene Expression
5%
Hazard Ratio
11%
Hemoglobin Determination
15%
Hodgkin's Lymphoma
10%
Infection
15%
International Prognostic Index
5%
Lymphoma Cell
15%
Malignant Neoplasm
31%
MALT Lymphoma
10%
Melphalan
5%
Memory B Cell
15%
Metastatic Carcinoma
5%
Multiple Myeloma
29%
Neutropenia
15%
Neutrophil
15%
Overall Survival
40%
Peripheral T-Cell Lymphoma
31%
Positron Emission Tomography-Computed Tomography
15%
Prognostic Factor
7%
Proportional Hazards Model
23%
Rituximab
15%
Socioeconomic Status
15%
Stem Cell Therapy
5%
T-Cell Lymphoma
5%
Venous Thromboembolism
15%
Vincristine
5%
Work Disability
15%
Keyphrases
5-year Survival
5%
Adjusted Hazard Ratio
5%
Affymetrix
15%
Alkylating Agents
5%
Anti-CD20 Antibody
5%
B-lineage
5%
Cancer Cell Phenotype
5%
Cancer Hallmarks
5%
Chemotherapy Outcomes
5%
Clinical Trial Participation
15%
Complex Cancer
15%
Cox Regression
6%
Deauville
7%
Diffuse Large B-cell Lymphoma (DLBCL)
31%
Disability Pension
13%
Discharge Diagnosis
6%
DNA Intercalation
5%
Drug Screening
5%
Drug Therapy
5%
First Cycle
15%
Gene Lists
5%
Genome-wide Microarray
15%
Global Gene Expression
5%
Human B Cells
15%
Late Infection
6%
Lymphoma
17%
MALT Lymphoma
7%
Mitotic Inhibitors
5%
Molecular Information
5%
Molecular Resistance Mechanism
5%
National Cohort Study
31%
Neuropathy Disability Score
11%
Neutropenia
15%
Neutrophil Count
10%
Neutrophils
15%
Nucleotide Variants
5%
Observational Prospective Study
5%
Outcome Prediction
15%
Primary Refractory Disease
5%
R-CHOP
15%
Remission Status
15%
Return to Work
15%
Screening Analysis
5%
Statistical Considerations
5%
Topoisomerase Inhibitors
5%
Transfusion Threshold
6%
Tumor mutational Burden
5%
Venous Thromboembolism
15%
Vincristine-induced Neuropathy
15%
Work Disability
15%
Immunology and Microbiology
B Cell
63%
Comorbidity
31%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Drug Dose Reduction
7%
Event Free Survival
7%
Hemoglobin Blood Level
15%
ICD-10
7%
Lymphoma Cell
17%
Medical Record
9%
Memory B Cell
15%
Molecular Epidemiology
15%
Neutrophil
15%
Neutrophil Count
15%
Overall Survival
39%
Positron Emission Tomography-Computed Tomography
31%
Promoter Region
7%
Rituximab
15%
Survival Rate
7%
T Cell
15%
Thymus
15%
